Resources from the same session
77MO - A first-in-human, open-label, dose-escalation study of ERK1/2 inhibitor HMPL-295 in patients with advanced solid tumors
Presenter: Rujiao Liu
Session: Mixed Proffered paper and Mini oral session: Developmental and precision medicine
Resources:
Abstract
Slides
Webcast
Invited Discussant 74MO, 75MO, 76MO and 77MO
Presenter: Irene Braña
Session: Mixed Proffered paper and Mini oral session: Developmental and precision medicine
Resources:
Slides
Webcast